Welcome! As the Novartis team in Brussels, we represent our company on European level and operate as the connecting piece between corporate, EU and trade associations.
Learn more about our priorities, how we reimagine medicine, get to know our team and stay in touch with us on LinkedIn.
Get to know our team members and what each of us is working on.
Learn about our business, strategy and performance in 2023, and how we create sustainable value for stakeholders and society.
To reimagine medicine is our overarching goal, therefore we are focusing on the general pharmaceutical legislation, EU competitiveness, open strategic autonomy, environmental sustainability as well as therapeutic areas.
The General Pharmaceutical Legislation is a once-in-a-generation opportunity to refine and evolve Europe’s regulatory framework – for a better future for patients and industry.
In the current geopolitical context, it is crucial for Europe to remain a leader in innovation, which includes research, clinical trials and manufacturing taking place in Europe.
As a company, we do everything to secure the supply of our medicines to patients. Europe is now increasingly focusing on how to ensure open strategic autonomy post-covid, and we want to be a constructive partner.
We understand the link between the health of our planet and the health of people. We are making progress in reducing the environmental impact of our operations in line with our near- and long-term targets.
At Novartis, we invest in the most promising frontiers of science, the most exciting innovations in the business of medicine, and the most significant healthcare needs.
*As of January 2024.
The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines for patients, healthcare systems, and society.
Stands for European Federation of Pharmaceutical Industries and Associations representing biopharmaceutical industry operating in Europe. EFPIA has a direct membership of 36 national associations and 39 leading pharmaceutical companies.
Is Europe's trade body for innovative companies working in the field of pharmaceuticals and medical technologies who are active in research, development of pharmaceuticals, biotechnologies and medical devices.
The European Association for Bioindustries, promotes an innovative and dynamic European biotechnology industry. They represent 78 corporate, associate members and bioregions & 15 national biotechnology associations representing over 1800 biotech SMEs.